Home: Oncology Leader Commentary: Kathy I. Pritchard, MD

Click on the topic below for comments by Dr Kathy I. Pritchard to comment on. You will also find links to related articles and clinical trials.

First-line trials of adjuvant Arimidex
Mechanism of action of Faslodex
Faslodex intramuscular injection
Faslodex and hot flashes
Faslodex and bone metabolism
Overview data on ovarian ablation
Adjuvant Zoladex
Endocrine effects of adjuvant chemotherapy

Faslodex intramuscular injection

Interview with Neil Love, MD from Breast Cancer Update for Medical Oncologists, Program 5 2000

Play Audio Below:

Dr. Pritchard: The good thing is that coming in every month and getting the injection is not a big problem. It’s a 5 cc injection, which for some reason terrorized everybody in the beginning, and we actually gave it in split doses, intramuscular injection. But in fact, you can give 5 cc’s or 2.5 cc’s twice and neither of them cause much in the way of local problems at all. It’s very well tolerated. It’s an injection but it doesn’t seem to be a big problem. I guess if this drug gets moved into the adjuvant setting, that could be more of an issue, but in the metastatic setting it doesn’t seem to be an issue for our patients at all. We’ve had some experience in the adjuvant setting using another injectable over a five year period, and actually once you get the mechanisms in place, it doesn’t seem to be a big issue. So, that’s as much as I can tell you about side effects of Faslodex, is the piece about the injections. We can’t tell which are the Faslodex injections and which are the placebo injections either so….

Dr. Love: That sounds like a good sign.

Dr. Pritchard: Yeah, I guess so.

Relevant Links:

Is ICI 182,780 an antiprogestin in addition to being an antiestrogen?
Zand, R. S. R.; Grass, L.; Magklara, A.; Jenkins, D. J. A., and Diamandis, E. P. (Reprint available from: Zand RSR Mt Sinai Hosp, Dept Pathol & Lab Med 600 Univ Ave Toronto ON M5G 1X5 Canada). Breast Cancer Research & Treatment. 60(1):1-8, 2000 Mar.

Selective estrogen receptor modulators: Structure, function, and clinical use [Review].
Osborne, C. K. and Fuqua, S. A. W. Journal of Clinical Oncology. 18(17):3172-3186, 2000 Sep.

Development of a novel, "pure" antiestrogen.
Howell, A.; Osborne, C. K.; Morris, C., and Wakeling, A. E. ICI 182,780 (Faslodex (TM)) -. Cancer. 89(4):817-825, 2000 Aug 15.

Similarities and distinctions in the mode of action of different classes of antioestrogens [Review].
Wakeling, A. E. Endocrine-Related Cancer. 7(1):17-28, 2000 Mar. No abstract

Approaches targeted to estrogen receptors for treatment of tamoxifen-resistant breast cancer: A brief overview.
Terakawa, N. (Reprint available from: Terakawa N Tottori Univ, Sch Med, Dept Obstet & Gynecol Yonago Tottori 683 Japan).. Oncology. 59(Suppl 1):3-4, 2000. No abstract

Treatment with the pure antiestrogen faslodex (ICI 182780) induces tumor necrosis factor receptor 1 (TNFR1) expression in MCF-7 breast cancer cells.
Smolnikar, K.; Loffek, S.; Schulz, T.; Michna, H., and Diel, P. (Reprint available from: Smolnikar K DSHS Cologne, Inst Morphol & Tumor Res Carl Diem Weg 6 D-50927 Cologne Germany). Breast Cancer Research & Treatment. 63(3):249-259, 2000 Oct. In process

Symposium overview: Estrogens and antiestrogens in managing the patient with breast cancer.
Newman, L. A.; Wood, W. C.; Sellin, R. V.; Morrow, M.; Vogel, C., and Singletary, S. E (Reprint available from: Singletary SE Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol 1515 Holcombe Blvd,Box 106 Houston, TX 77030 USA).. Annals of Surgical Oncology. 7(8):568-574, 2000 Sep. In process

Top of Page